Related Experiment Video
Updated: May 10, 2026

12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?
1Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine & Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan. ttanak@imed3.med.osaka-u.ac.jp
Immunotherapy
|July 9, 2013
Summary
Tocilizumab (TCZ) treatment for rheumatoid arthritis (RA) patients showed a trend toward increasing the regulatory T cell (Treg) to T helper type 17 (Th17) cell ratio. Further studies are needed to confirm this effect in RA.
Area of Science:
- Immunology
- Rheumatology
Background:
- Tocilizumab (TCZ), an anti-interleukin-6 (IL-6) receptor antibody, is effective for rheumatoid arthritis (RA).
- IL-6 blockade may correct the Treg/Th17 imbalance in RA, but mechanisms are unclear.
Purpose of the Study:
- To investigate the effect of TCZ on the Treg/Th17 cell balance in RA patients.
- To explore potential mechanisms of TCZ's efficacy in RA.
Main Methods:
- Analysis of peripheral CD4+ T cells from eight active RA patients.
- Evaluation of Treg and Th17 cell ratios during 24 weeks of TCZ treatment.
Main Results:
- A trend towards an increased Treg/Th17 cell ratio was observed during TCZ treatment.
- This preliminary study suggests a potential immunomodulatory effect of TCZ.
Conclusions:
- TCZ treatment may influence the Treg/Th17 balance in RA patients.
- Further research is required to validate these findings and elucidate the precise mechanisms.

